NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

With the FDA approval of larotrectinib, NTRK fusion assessment has recently become a standard part of management for patients with locally advanced or metastatic cancers. Unlike somatic mutation assessment, the detection of NTRK fusions is not straightforward, and various assays exist at the DNA, RN...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mod Pathol
Egile Nagusiak: Solomon, James P., Linkov, Irina, Rosado, Andrea, Mullaney, Kerry, Rosen, Ezra Y., Frosina, Denise, Jungbluth, Achim A., Zehir, Ahmet, Benayed, Ryma, Drilon, Alexander, Hyman, David M., Ladanyi, Marc, Sireci, Anthony N., Hechtman, Jaclyn F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437403/
https://ncbi.nlm.nih.gov/pubmed/31375766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41379-019-0324-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak